Can I Take Melatonin with Belsomra (Suvorexant)?
Suvorexant, sold under the brand name Belsomra, is an FDA-approved dual orexin receptor antagonist (DORA) used for insomnia in adults. Melatonin is an over-the-counter hormone supplement, not FDA-approved as a drug in the United States, commonly taken for sleep onset or circadian adjustment. No dedicated clinical trial of the two taken together has been identified, so this page describes what is pharmacologically established, what is plausible, and what remains unverified.
Direct answer: There is no known pharmacokinetic drug interaction between suvorexant and melatonin, because they act on different receptors and are cleared through different metabolic pathways. The concern is pharmacodynamic: both compounds promote sleep and reduce arousal through separate mechanisms, so their sedating effects can add together. That additive effect is a reasonable pharmacological inference, not a finding from a controlled trial in this specific combination, and it means the combination carries a higher plausible risk of next-day grogginess and impaired driving than either agent alone.
What Belsomra (suvorexant) does and why timing matters
Suvorexant blocks orexin-A and orexin-B from binding to their receptors (OX1R and OX2R) in brain regions that drive wakefulness. Reducing orexin signaling lowers the brain's arousal drive, which is the mechanism behind its FDA-approved insomnia indication. The FDA approved suvorexant in 2014, and the current prescribing information remains the authoritative source for its dosing, warnings, and approved use.
The approved dose range is 5 mg to 20 mg once nightly, taken within 30 minutes of bedtime. The label warns that doses above 10 mg raise the risk of next-day impairment, including impaired driving, and suvorexant carries a boxed warning for complex sleep behaviors such as sleepwalking and sleep-driving, some occurring without memory of the event. Readers should verify current dosing and warning language directly against the label linked above, since labeling can be updated after this article's publication date.
Suvorexant's elimination half-life is commonly cited as roughly 12 hours, which means a meaningful fraction of the dose is still circulating the following morning. That long half-life is the main reason clinicians are cautious about adding any other sedating substance in the same 24-hour window, including melatonin taken that evening or the next night.
What melatonin does, and why "natural" does not mean risk-free
Exogenous melatonin binds MT1 and MT2 receptors in the suprachiasmatic nucleus, the brain's circadian pacemaker, and shifts the timing of sleep onset. It is sold as a dietary supplement in the United States, which means it is not subject to the same manufacturing and potency oversight as an FDA-approved drug. Independent testing of commercial melatonin products has previously found substantial variability between labeled and actual content in some samples; the exact magnitude of that variability should be verified against current, product-specific testing rather than assumed, because supplement formulations and manufacturers change over time. This variability matters for an interaction discussion because a "3 mg" label does not guarantee a 3 mg dose is what a patient actually takes.
Is the melatonin-suvorexant interaction pharmacokinetic or pharmacodynamic?
This is the question that determines how seriously to treat the combination.
A pharmacokinetic interaction changes how a drug is absorbed, metabolized, or cleared, altering blood levels. A pharmacodynamic interaction changes the net effect at the target tissue even when blood levels of each drug are unaffected. Suvorexant and melatonin act on separate receptor systems and are generally understood to be metabolized through different pathways, which is why they are not expected to raise or lower each other's blood concentration in a clinically important way. That absence of a pharmacokinetic interaction should not be read as an absence of risk.
The interaction that matters here is pharmacodynamic: both agents reduce wakefulness through independent routes, and additive central nervous system depression across sedating drug classes is a well-established general pharmacological principle. Applying that principle to this specific pairing is a reasonable extrapolation, not a directly studied outcome. No published randomized trial specifically testing suvorexant plus melatonin, with driving-simulation or polysomnography endpoints, has been identified for this review. The absence of a dedicated trial is not evidence that the combination is safe; it means the risk estimate here rests on mechanism and on each drug's individual safety data, not on direct combination data.
What are the specific plausible risks?
Prolonged sleep inertia. Grogginess and disorientation on waking are documented adverse effects of suvorexant alone, per the FDA label. Adding melatonin, especially an extended-release formulation with a longer duration of receptor activity, plausibly lengthens the window during which both drugs are promoting sleep, which could extend morning grogginess. This is a mechanistic inference and has not been quantified in controlled studies of the combination.
Impaired morning driving. The suvorexant label describes next-day psychomotor impairment, including driving impairment, particularly at the 20 mg dose. No combination-specific driving study exists. Patients who must drive within 8 hours of a suvorexant dose should treat any added sedating supplement as a reason for extra caution, not as a neutral addition.
Complex sleep behaviors. Suvorexant's boxed warning covers sleepwalking, sleep-driving, and similar behaviors occurring with suvorexant alone. Whether melatonin co-use changes the frequency of these events is not established in controlled data. The theoretical concern, that deeper combined sedation could worsen dissociation between behavior and awareness, is plausible but unproven.
Metabolic effects of higher-dose melatonin. Melatonin receptors are expressed on pancreatic beta cells, and there is a body of physiological and genetic research linking melatonin signaling to insulin secretion and glucose regulation. Patients with diabetes or prediabetes who take higher-dose melatonin (commonly available as 3 mg, 5 mg, or 10 mg tablets) alongside suvorexant should raise this with their prescriber and discuss whether glucose monitoring is warranted; this is a general metabolic consideration about melatonin itself, not something demonstrated to be worsened by suvorexant specifically.
Who is at higher risk from this combination
- Older adults. Reduced drug clearance with age is the basis for the FDA label's recommendation to start suvorexant at the lowest dose in this population. Slower clearance means melatonin's additive sedation lands on top of a higher residual suvorexant level, and falls during nighttime waking are a specific practical concern.
- People taking CYP3A4 inhibitors. Suvorexant is metabolized through CYP3A4. Drugs or substances that inhibit this enzyme (certain antifungals, some cardiac medications, and large amounts of grapefruit) can raise suvorexant blood levels. Adding melatonin on top of an already elevated suvorexant level increases the plausible sedation burden.
- People with obstructive sleep apnea. The suvorexant label advises against use in severe untreated OSA. Because both suvorexant and melatonin may reduce upper-airway muscle tone during sleep, patients with moderate-to-severe OSA who are not adequately treated should discuss this specifically before adding any sleep supplement.
Evidence-status interaction assessment
| Status | Claim | Basis |
|---|---|---|
| Established | Suvorexant is FDA-approved for insomnia; melatonin is an unregulated OTC supplement, not an FDA-approved drug for this use | FDA label and general FDA supplement regulation status |
| Established | Suvorexant and melatonin act on different receptor systems (orexin vs. MT1/MT2) | Basic pharmacology of each agent, described in the FDA label and standard pharmacology references |
| Established | Suvorexant carries a boxed warning for complex sleep behaviors and a label warning for next-day impairment, especially above 10 mg | FDA label |
| Plausible, not directly tested | Combining suvorexant with melatonin produces additive CNS depression greater than either agent alone | Extrapolated from the general principle of additive sedative-hypnotic effects; no dedicated combination trial identified |
| Plausible, not directly tested | Melatonin lengthens suvorexant-associated sleep inertia or next-day grogginess | Mechanistic inference from each drug's individual sedation profile |
| Not established | A specific "safe" melatonin dose to combine with a specific suvorexant dose | No controlled dose-finding study of the combination identified |
| Not established | Whether melatonin changes the frequency of suvorexant-associated complex sleep behaviors | No combination-specific safety data identified |
| Requires clinician/pharmacist verification | Exact incidence rates of somnolence, driving impairment, or sleep inertia cited for suvorexant alone | Confirm against the current FDA label version at time of prescribing, since incidence data can be updated |
| Requires clinician/pharmacist verification | Actual melatonin content of a specific product the patient is using | Supplement labeling is not FDA-regulated to the same standard as drug labeling; content can vary by manufacturer and batch |
A practical framework for deciding whether to combine them
Step 1: Clarify the goal. Melatonin's clearest evidence-supported use is shifting circadian timing (jet lag, shift work, delayed sleep phase), using low doses taken hours before the target bedtime, not as a general sedative taken alongside a prescription hypnotic.
Step 2: Look at the suvorexant dose. Patients on the lowest effective suvorexant dose have less residual drug on board at the time melatonin would be active, which lowers, but does not eliminate, the plausible additive-sedation concern.
Step 3: Screen for the higher-risk groups above. Older age, OSA, diabetes or prediabetes, and CYP3A4-inhibitor use each raise the stakes of combining sedating agents and are reasons to involve a prescriber before adding melatonin, not after.
Step 4: If a prescriber approves co-use, favor the lowest melatonin dose and immediate-release formulation, and avoid extended-release products unless there is a specific reason to prefer them, since a longer duration of receptor activity plausibly extends the sedation overlap window.
Step 5: Report the combination. Melatonin is not automatically visible in electronic prescribing systems because it is sold OTC. Bring the actual bottle to appointments so the prescriber can see the labeled dose and formulation.
When this is not a supplement decision
Anyone experiencing confusion, unexplained injuries, memory gaps around nighttime hours, signs of sleepwalking or sleep-driving, or difficulty staying awake during the day after starting or combining these agents should contact their prescriber promptly rather than adjusting doses independently. New or worsening depression, suicidal thoughts, or allergic reactions (swelling, difficulty breathing) after starting suvorexant warrant urgent medical attention, consistent with the general warnings on the FDA label.
What this page does not establish
This review does not identify a controlled trial testing suvorexant and melatonin together, so it cannot state a specific safe dose, a quantified increase in impairment risk, or a defined rate of adverse events for the combination. Statements about additive sedation rest on standard pharmacological reasoning about sedative-hypnotic drug classes generally, applied to this pair. A pharmacist or prescriber reviewing a specific patient's full medication list, kidney and liver function, and comorbidities is the appropriate source for an individualized decision, not this article.
References
This article is intended for general education. Reported figures and statements vary between studies and have not been independently confirmed here, so readers should consult qualified medical sources for specific data or guidance.